Recent Updates
Recently added Catalysts
INO Positive Sentiment

INOVIO to Report First Quarter 2024 Financial Results on May 13, 2024

Monday, April 29, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: INOVIO (NASDAQ:INO) announced that it will report its first quarter 2024 financial results on May 13, 2024, after the market closes. The company specializes in DNA medicines aimed at treating various diseases, including HPV-related illnesses and cancer. Following the financial report, INOVIO will host a live conference call and webcast to discuss the results and provide updates on its business. This event underscores INOVIO's ongoing commitment to transparency and stakeholder engagement.
Price reaction · baseline $10.57 (2024-04-26 close) · 1 other INO headline(s) in the window, move may be shared
day 0 close
+8.8%
day 1
+8.3%
day 3 · peak
+13.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • INOVIO is expected to release its financial results, indicating ongoing corporate activity.
  • The company continues its focus on innovative DNA medicines, suggesting potential for advancement in treatments.
  • A live conference call will engage analysts and provide transparency to stakeholders.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~6 mo
High dilution risk
Lead asset
VGX-410
Phase 2 · Hepatitis C Virus Infection

Full Press Release Details

PLYMOUTH MEETING, Pa., April 29, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that first quarter 2024 financial results will be released after the market close on May 13, 2024. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update.
The live webcast will be available online at http://ir.inovio.com/events-and-presentations/default.aspx. This is a listen-only event but will include a live Q&A with analysts. The webcast will be archived and available for replay for 90 days following the event.
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.

Frequently Asked Questions

When will INOVIO announce its Q1 2024 financial results?

INOVIO will announce its Q1 2024 financial results on May 13, 2024.

How can I access INOVIO's live conference call?

The live conference call can be accessed at http://ir.inovio.com/events-and-presentations/default.aspx.

What is the focus of INOVIO's research?

INOVIO focuses on developing DNA medicines for HPV-related diseases, cancer, and infections.

Will there be a Q&A session during the webcast?

Yes, the webcast will include a live Q&A session with analysts.

How long will the webcast be available for replay?

The webcast will be available for replay for 90 days after the event.

ShareAdd on Google
Tags: INO Viatris Investor Conferences Healthcare INOVIO financial results biotechnology HPV cancer
Last updated: Apr 29, 2024

Biotech snapshot

Cash runway
$37M liquidity · $6M/mo burn
~6 mo
High dilution risk
Lead asset
VGX-410Phase 2
Hepatitis C Virus Infection →